• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Nu Skin Enterprises Inc.

    6/2/25 4:25:09 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care
    Get the next $NUS alert in real time by email
    S-8 1 ef20049856_s8.htm FORM S-8
    As filed with the Securities and Exchange Commission on June 2, 2025.
     
    Registration No. 333-______

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
     
    NU SKIN ENTERPRISES, INC.
    (Exact name of registrant as specified in its charter)


    Delaware
     
    87-0565309
    (State or other jurisdiction of incorporation or organization)
     
    (I.R.S. Employer Identification No.)
     
    75 West Center Street
    Provo, Utah 84601
    (Address of Principal Executive Offices) (Zip Code)
     
    Nu Skin Enterprises, Inc. Amended and Restated 2024 Omnibus Incentive Plan
    (Full title of the plan)
     
    Chayce D. Clark
    Executive Vice President and General Counsel
    Nu Skin Enterprises, Inc.
    75 West Center Street
    Provo, Utah 84601
     (801) 345-1000
    (Name, address and telephone number, including area code, of agent for service)
     
    With copies to:
    Jay H. Knight
    Barnes & Thornburg LLP
    1600 West End Avenue, Suite 800
    Nashville, TN 37203-3494
    (615) 621-6100


     
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
     
    Large accelerated filer
    ☐  
    Accelerated filer
    ☑
    Non-accelerated filer
    ☐  
    Smaller reporting company
    ☐
         
    Emerging growth company
    ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐
     


    EXPLANATORY NOTE
     
    This Registration Statement on Form S-8 is being filed by Nu Skin Enterprises, Inc. (the “Company”), a Delaware corporation, for the purpose of registering 790,000 additional shares of Company Class A common stock, par value $0.001 (the “Common Stock”), for issuance under the Company’s Amended and Restated 2024 Omnibus Incentive Plan (the “Amended Plan”).  On March 31, 2025, the Company’s Board of Directors approved the Amended Plan, which amends and restates the 2024 Omnibus Incentive Plan effective as of June 5, 2024 (the “Plan”) in its entirety.  The Amended Plan was later approved by the Company’s stockholders at the 2025 Annual Meeting of Stockholders.
     
    The 790,000 additional shares of Common Stock available for issuance under the Amended Plan registered pursuant to this Registration Statement are the same class as those registered on the Registration Statement on Form S-8 on June 7, 2024 (File No. 333-280044) (the “Prior Registration Statement”), which is currently effective. Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statement, including any amendments thereto or filings incorporated therein, are incorporated herein by reference, except as modified, supplemented or superseded herein.
     
    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
     
    Item 3.
    Incorporation of Documents by Reference.
     
    The following documents, which have been filed with the Securities and Exchange Commission (the “Commission”) by the Company, are incorporated by reference in this Registration Statement, except to the extent that information therein is deemed furnished and not filed pursuant to securities laws and regulations:
     

    (a)
    the Company’s Annual Report on Form 10-K for the year ended December 31, 2024;
     

    (b)
    the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025;
     

    (c)
    the Company’s Current Reports on Form 8-K filed on January 3, 2025, March 6, 2025, and May 30, 2025; and
     

    (d)
    the description of the Company’s Class A Common Stock filed as Exhibit 4.2 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed on February 15, 2024, together with any amendment or report filed with the Commission for the purpose of updating such description.
     
    All documents filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), subsequent to the date hereof and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities remaining unsold shall be deemed to be incorporated by reference herein and to be a part hereof from the respective dates of filing of such documents.
     
    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is, or is deemed to be, incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
     

    Item 8.
    Exhibits.
     
    Unless otherwise noted, the SEC file number for exhibits incorporated by reference is 001-12421.
     
    Exhibit Number
    Description of Document
    4.1
    Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-1 filed September 16, 1996, File No. 333-12073).
       
    4.2
    Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.2 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2009, filed March 1, 2010).
       
    4.3
    Certificate of Designation, Preferences and Relative Participating, Optional and Other Special Rights of Preferred Stock and Qualifications, Limitations and Restrictions Thereof (incorporated by reference to Exhibit 3.3 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2004, filed March 15, 2005).
       
    4.4
    Sixth Amended and Restated Bylaws of Nu Skin Enterprises, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed November 1, 2024).
       
    4.5
    Specimen Form of Stock Certificate for Class A Common Stock (incorporated by reference to Exhibit 4.1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed February 16, 2023).
       
    5.1*
    Opinion of Barnes & Thornburg LLP.
       
    23.1*
    Consent of Barnes & Thornburg LLP (included as part of Exhibit 5.1).
       
    23.2*
    Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.
       
    24.1*
    Power of Attorney (included in the signature pages to this Registration Statement).
       
    99.1
    Nu Skin Enterprises, Inc. Amended and Restated 2024 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed May 30, 2025).
       
    107.1*
    Filing Fee Table.


    *
    Filed herewith
     

    SIGNATURES
     
    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S‑8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Provo, State of Utah, on this 2nd day of June, 2025.
     
     
    NU SKIN ENTERPRISES, INC.
         
     
    By:
    /s/ Ryan S. Napierski
     
    Name:
    Ryan S. Napierski
     
    Title:
    President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Ryan S. Napierski, Chayce D. Clark and Gregory S. Belliston, and each of them, any of whom may act without joinder of the other, the individual’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for the person and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and all documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney shall be governed by and construed with the laws of the State of Delaware and applicable federal securities laws.
     
    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities indicated on the 2nd day of June, 2025.

    Signature

    Title



    /s/ Steven J. Lund

    Executive Chairman of the Board
    Steven J. Lund




    /s/ Ryan S. Napierski

    President, Chief Executive Officer and Director
    (Principal Executive Officer)
    Ryan S. Napierski




    /s/ James D. Thomas

    Chief Financial Officer
    (Principal Financial Officer and Accounting Officer)
    James D. Thomas




    /s/ Emma S. Battle

    Director
    Emma S. Battle




    /s/ Daniel W. Campbell

    Director
    Daniel W. Campbell




    /s/ Laura Nathanson

    Director
    Laura Nathanson




    /s/ Thomas R. Pisano

    Director
    Thomas R. Pisano




    /s/ James M. Winett

    Director
    James M. Winett




    /s/ Edwina D. Woodbury

    Director
    Edwina D. Woodbury




    /s/ Mark A. Zorko

    Director
    Mark A. Zorko




    Get the next $NUS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NUS

    DatePrice TargetRatingAnalyst
    1/31/2023$43.00 → $39.00Buy → Hold
    Jefferies
    2/17/2022$47.00 → $50.00Neutral
    DA Davidson
    11/24/2021$43.00 → $49.00Neutral
    Citigroup
    10/6/2021$61.00 → $47.00Neutral
    DA Davidson
    More analyst ratings

    $NUS
    Financials

    Live finance-specific insights

    See more
    • Nu Skin Enterprises Reports First Quarter Revenue at High End of Guidance

      Nu Skin Enterprises Inc. (NYSE:NUS) today announced first quarter revenue at the high end of its guidance range. Executive Summary Q1 2025 vs. Prior-year Quarter Revenue $364.5 million; (12.7)% (3.0)% FX impact or $(12.3) million Earnings Per Share (EPS) $2.14 or $0.23 excluding Mavely gain and other charges compared to $(0.01) or $0.09 excluding restructuring charges Customers 776,712; (11)% Paid Affiliates 131,518; (15)% Sales Leaders 31,036; (20)% "We are pleased to achieve revenue at the high end of our guidance range and exceed our adjusted earnings forecast to start out the year," said Ryan Napierski, Nu Skin president and CEO. "We drove

      5/8/25 4:06:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Announces Quarterly Dividend

      Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on June 11, 2025, to shareholders of record on May 30, 2025. About Nu Skin Enterprises, Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which

      5/8/25 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises to Announce First Quarter 2025 Financial Results

      Nu Skin Enterprises, Inc. (NYSE:NUS) today announced it will release first quarter 2025 results after the market closes on Thursday, May 8. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives. The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company's website at ir.nuskin.com. A replay of the webcast will be available at the same location through Thursday, May 22. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of

      4/2/25 4:15:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    $NUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

      SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      11/12/24 4:47:17 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

      SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      11/6/24 10:20:59 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

      SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      11/4/24 10:21:31 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    $NUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Campbell Daniel W was granted 18,008 shares, increasing direct ownership by 60% to 48,262 units (SEC Form 4)

      4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

      6/3/25 5:50:59 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Director Nathanson Laura was granted 18,008 shares, increasing direct ownership by 83% to 39,638 units (SEC Form 4)

      4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

      6/3/25 5:49:32 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Director Thomas Pisano R. was granted 18,008 shares, increasing direct ownership by 25% to 90,184 units (SEC Form 4)

      4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

      6/3/25 5:45:17 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    $NUS
    Leadership Updates

    Live Leadership Updates

    See more

    $NUS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nu Skin Enterprises Appoints James Winett to Board of Directors

      Nu Skin Enterprises (US:NYSE) today announced the appointment of James Winett, a managing member of SIZE Advisory Group, to the company's board of directors. He was elected by shareholders at the annual shareholder meeting for Nu Skin Enterprises. "Jim adds extensive expertise in strategic planning, operations and finance from his many years of consulting experience," said Steven J. Lund, executive chairman of the board. "He will also be an asset to our Rhyz businesses with his background in corporate transactions and advising small businesses and start-ups. We welcome Jim to the board and look forward to tapping into his insights and experience." Winett is a managing member of SIZE Adv

      6/2/25 12:19:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Appoints Mark A. Zorko to Board of Directors

      Nu Skin Enterprises (NYSE:NUS) today announced the appointment of Mark A. Zorko, a principal with executive management association Brentwood Advisory Group, to the company's board of directors. The board also appointed Zorko to serve on its audit committee and the nominating and corporate governance committee. "Mark brings extensive C-level leadership experience with several global public companies, as well as more than 20 years of board-level experience," said Steven J. Lund, executive chairman of the board. "We welcome Mark to the board and look forward to leveraging his extensive business insights and experience." Zorko is a principal with Brentwood Advisory, an association he co-found

      9/12/24 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

      9/6/24 6:43:00 PM ET
      $AAL
      $ADMA
      $ADNT
      $AMCX
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Nu Skin Enterprises Appoints James Winett to Board of Directors

      Nu Skin Enterprises (US:NYSE) today announced the appointment of James Winett, a managing member of SIZE Advisory Group, to the company's board of directors. He was elected by shareholders at the annual shareholder meeting for Nu Skin Enterprises. "Jim adds extensive expertise in strategic planning, operations and finance from his many years of consulting experience," said Steven J. Lund, executive chairman of the board. "He will also be an asset to our Rhyz businesses with his background in corporate transactions and advising small businesses and start-ups. We welcome Jim to the board and look forward to tapping into his insights and experience." Winett is a managing member of SIZE Adv

      6/2/25 12:19:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Reports First Quarter Revenue at High End of Guidance

      Nu Skin Enterprises Inc. (NYSE:NUS) today announced first quarter revenue at the high end of its guidance range. Executive Summary Q1 2025 vs. Prior-year Quarter Revenue $364.5 million; (12.7)% (3.0)% FX impact or $(12.3) million Earnings Per Share (EPS) $2.14 or $0.23 excluding Mavely gain and other charges compared to $(0.01) or $0.09 excluding restructuring charges Customers 776,712; (11)% Paid Affiliates 131,518; (15)% Sales Leaders 31,036; (20)% "We are pleased to achieve revenue at the high end of our guidance range and exceed our adjusted earnings forecast to start out the year," said Ryan Napierski, Nu Skin president and CEO. "We drove

      5/8/25 4:06:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Announces Quarterly Dividend

      Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on June 11, 2025, to shareholders of record on May 30, 2025. About Nu Skin Enterprises, Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which

      5/8/25 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    $NUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Nu Skin downgraded by Jefferies with a new price target

      Jefferies downgraded Nu Skin from Buy to Hold and set a new price target of $39.00 from $43.00 previously

      1/31/23 6:17:27 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • DA Davidson reiterated coverage on Nu Skin Enterprises with a new price target

      DA Davidson reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $50.00 from $47.00 previously

      2/17/22 4:46:52 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Citigroup reiterated coverage on Nu Skin Enterprises with a new price target

      Citigroup reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $49.00 from $43.00 previously

      11/24/21 11:03:39 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    $NUS
    SEC Filings

    See more
    • SEC Form S-8 filed by Nu Skin Enterprises Inc.

      S-8 - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

      6/2/25 4:25:09 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

      5/30/25 4:05:53 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • SEC Form SD filed by Nu Skin Enterprises Inc.

      SD - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

      5/27/25 6:01:26 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    $NUS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Product Officer Hatchett Steven Keith bought $49,010 worth of shares (6,500 units at $7.54), increasing direct ownership by 4% to 162,065 units (SEC Form 4)

      4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

      5/28/25 6:26:44 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care